Trump administration battles courts over immigration enforcement, seeking to lift restrictions on controversial practices.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.
Trump administration battles courts over immigration enforcement, seeking to lift restrictions on controversial practices.
Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making it a top performer in the S&P 500 and Nasdaq 100.